Table 3. Outcomes and cost results.
|
Standard treatment |
Alanyl-glutamine treatment |
Savings |
||||
|---|---|---|---|---|---|---|
| Mean | s.e. | Mean | s.e. | Mean | s.e. | |
| Reduction in hospital LOS (days) | 30.45 | 0.81 | 29.38 | 0.97 | 1.07 | 0.83 |
| Deaths per 10 000 patients | 2598 | 406 | 1845 | 377 | 753 | 250 |
| Infections per 10 000 patients | 1165 | 243 | 918 | 209 | 247 | 91 |
| Total cost (€) | 29 724 | 4218 | 28 677 | 4066 | 1047 | 823 |
| Hospital cost (€) | 29 594 | 4216 | 28 206 | 4061 | 1388 | 815 |
| Infection cost (€) | 130 | 37 | 102 | 31 | 28 | 11 |
| Glutamine cost (€) | 0 | 0 | 369 | 101 | −369 | 101 |
| CER (€/patient discharged alive) | 40 156 | 5969 | 35 165 | 5181 | 4991 | 1534 |
Abbreviations: CER, cost-effectiveness ratio; LOS, length of stay.